

Showcasing research from Professor Wagner's laboratory, Department of Physics, Saarland University, Saarbruecken, Germany.

Impact of anti-coagulant choice on blood elongational behavior

Blood's rheological properties impact how it flows through our vascular system. Complex, non-Newtonian flow properties might lead to new and unexpected flow phenomena such as viscoelastic turbulence or turbulent drag reduction. This study examines the effects of anticoagulants on human and swine blood elongational properties. Citrate aligned the most with physiological values from untreated human blood droplets. This is a significant result not only for physiological flow, but also for *in vitro* studies or for forensic investigations on blood stains.

Image credit: Ron Christmann

As featured in:



See Jorge Eduardo Fiscina *et al.*, *Soft Matter*, 2024, **20**, 4561.



Cite this: *Soft Matter*, 2024,  
20, 4561

Received 5th February 2024,  
Accepted 16th May 2024

DOI: 10.1039/d4sm00178h

[rsc.li/soft-matter-journal](https://rsc.li/soft-matter-journal)

## Impact of anti-coagulant choice on blood elongational behavior

Jorge Eduardo Fiscina,<sup>\*a</sup> Alexis Darras,<sup>b</sup> Daniel Attinger<sup>c</sup> and Christian Wagner<sup>id</sup><sup>bd</sup>

Blood is a highly complex fluid with rheological properties that have a significant impact on various flow phenomena. In particular, it exhibits a non-Newtonian elongational viscosity that is comparable to polymer solutions. In this study, we investigate the effect of three different anticoagulants, namely EDTA (ethylene diamine tetraacetic acid), heparin, and citrate, on the elongational properties of both human and swine blood. We observe a unique two stage thinning process and a strong dependency of the characteristic relaxation time on the chosen anticoagulant, with the longest relaxation time and thus the highest elongational viscosity being found for the case of citrate. Our findings for the latter are consistent with the physiological values obtained from a dripping droplet of human blood without any anticoagulant. Furthermore, our study resolves the discrepancy found in the literature regarding the reported range of characteristic relaxation times, confirming that the elongational viscosity must be taken into account for a full rheological characterization of blood. These results have important implications for understanding blood flow in various physiological, pathological and technological conditions.

## 1 Introduction

Blood is a complex fluid that exhibits a range of rheological properties, including shear thinning, viscoelasticity, thixotropy, and yield stress, particularly at physiological hematocrit.<sup>1–4</sup> Recently, it has been demonstrated that blood also displays a high elongational viscosity.<sup>5–9</sup> This behavior arises from the elasticity of plasma proteins, similar to that observed for flexible synthetic polymers.<sup>10–15</sup> The presence of an elevated elongational viscosity can have a significant impact on various flow phenomena, such as turbulent drag reduction,<sup>16,17</sup> viscoelastic instabilities,<sup>18–20</sup> and inhibition of drop splashing.<sup>21</sup> Therefore, a quantitative understanding of the magnitude of the elongational viscosity is essential for studying physiological blood flow, including vascular flow instabilities,<sup>22</sup> as well as for the design and optimization of biomedical devices, such as cell sorters<sup>23</sup> and ventricular assist devices,<sup>24</sup> and for forensic investigations of blood stains.<sup>9,25,26</sup>

Measuring the elongational viscosity of low-viscosity fluids is a challenging task. Besides some microfluidic technologies,<sup>27</sup> the most established method is the capillary break-up extensional rheometry (CaBER) that involves observing the thinning

process of a capillary bridge between two plates that are drawn apart. While the neck of a Newtonian fluid breaks up into self-similar solutions,<sup>28</sup> the change of the conformational state of the polymers and the resulting build-up of elastic stresses inhibits breakage. This results typically in the formation of a cylindrical filament with a pure elongational flow<sup>29</sup> that thins exponentially over time. Alternatively, one can also observe the capillary thinning of dripping droplets, but in general, CaBER offers better control of the thinning process and better image quality.<sup>30,31</sup> Recently the dripping-on-substrate technique was introduced as an alternative method to characterise the elongational properties of low viscous non-Newtonian fluids.<sup>32</sup> The balance of capillary pressure and elastic stresses leads to an exponential thinning behavior, and in some cases the characteristic timescale  $\lambda_C$  can be indirectly related to the polymer relaxation time *via* scaling laws.<sup>14,33</sup> Additionally,  $\lambda_C$  is directly proportional to the apparent elongational viscosity, which can be orders of magnitude larger than the shear viscosity measured in standard rheometers.<sup>12</sup> It is important to note that the capillary bridge shrinks only due to capillary forces with an elongational rate that is, according to the simple models, exactly 3 times the polymer relaxation time. Consequently, one cannot give any statement on the rate dependent elongational viscosity.<sup>13</sup>

The shear thinning and (visco-)elastic properties of blood in shear rheology result mostly from the formation of aggregates of red blood cells at low shear rates and stasis, the so-called rouleaux. They form a weak, fragile colloidal gel which leads to a small yield stress and shear thinning at larger shear rates.<sup>3,4</sup>

<sup>a</sup> Saarland University, Physics Department, 66123 Saarbruecken, Germany.

E-mail: [j.fiscina@mx.uni-saarland.de](mailto:j.fiscina@mx.uni-saarland.de)

<sup>b</sup> Saarland University, Physics Department, 66123 Saarbruecken, Germany

<sup>c</sup> Struo LLC, Ames, Iowa 50010, USA

<sup>d</sup> University of Luxembourg, Physics and Materials Science Research Unit, 1511 Luxembourg, Luxembourg



The blood cells are suspended in an aqueous buffer solution, the plasma, that contains in average  $70 \text{ g l}^{-1}$  of proteins, of which some have a large molecular weight of up to 1.3 Mio amu. The plasma itself has no measurable elastic effect in shear rheometry, only a surface layer of proteins at the plasma-air interface can lead to misleading data and of course such a surface film does not exist in physiological flow.<sup>34</sup> It was shown in two independent studies by replacing the surrounding air by oil in a CaBER experiment that such a protein surface film does not play a significant role in capillary thinning experiments of blood.<sup>5,7</sup>

In pure elongational flow, polymers are aligned with the flow and most efficiently stretched which leads to the high elongational viscosity. Consequently, the plasma proteins are the microscopic constituents that are responsible for the elongational properties of blood and washed red blood cells in a buffer solution without any proteins do not show any viscoelastic filament in capillary thinning experiments,<sup>5</sup> but of course the presence of the red blood cells can still alter the pinch-off process of the Newtonian suspending medium.<sup>35,36</sup> Of course, the red blood cells experience a strong elongational flow field that might lead to strong deformations or even haemolysis,<sup>37,38</sup> but those effects are beyond the scope of this study. While there is now unanimous agreement that plasma and thus also blood have an extensional viscosity, the statements about the characteristic time scale  $\lambda_C$  vary by more than an order of magnitude.<sup>5-9</sup> Even if the specific protocol of the capillary break-up measurement might play a role here, this effect is much too large for being the sole mechanism. We therefore hypothesized that the anticoagulant in use might play an important role.

In this study, we compare the effect of EDTA (ethylene diamine tetraacetic acid), heparin, and citrate on the elongational properties of blood. All three are commonly used anticoagulants in clinical settings and they work by different mechanisms to prevent blood from clotting. Anticoagulation is achieved either by the binding of calcium ions (EDTA, citrate) or by the inhibition of thrombin (heparin). However, the biochemical effects of these substances is far more complex and goes beyond the scope of our study.<sup>39-41</sup> To test the generality of our findings and due to its relevance as a replacement fluid for *in vitro* studies, we performed this study not only on human blood but also on swine blood.<sup>9</sup>

## 2 Materials and methods

### 2.1 Experimental set-up

The capillary break-up extensional rheometer set-up is a lab-made upgrade of the apparatus described in a previous work.<sup>31</sup> It consists of two copper discs with a diameter of 4 mm, where the lower disc is fixed and the upper disc can be moved in the *z*-direction with a linear motor (P01-23  $\times$  80, Linmot, Spreitenbach, Switzerland). A droplet of blood with a specified volume is placed with a micro-pipette between the two plates. The initial gap distance between the disks is 2 mm and the linear motor pulls the upper disk with a constant speed of

$0.1 \text{ mm s}^{-1}$ , according to the slow retraction method (SRM) that is best suited for low viscous fluids with short relaxation times.<sup>30</sup> The pending (dripping) droplet experiments is done by connecting a reservoir filled with the anticoagulant-treated blood to a Teflon nozzle with a diameter of 2 mm or, for the case of the untreated blood, by connecting a Teflon tube from a venous punctured person directly to the nozzle. The dripping frequency is controlled by a manual valve (Discofix 3SC, B. Braun Melsungen AG, Germany) which allows to tune the hydraulic resistance of the Teflon tube. For all experiments, an LED illumination (ZLED CLS 9000, Zett Optics GmbH, Braunschweig, Germany) is used to project a shadow image of the capillary bridge. All experiments were performed at room temperature ( $22 \text{ }^\circ\text{C}$ ). Due to the small diameter of the Teflon tube, we assume that the untreated blood from the venous punctured person has reached room temperature when it reaches the nozzle. We follow the evolution of the filament with a 10-bit high-speed camera (X-Stream XS-5, IDT, Tallahassee, USA) at up to 1.54 kHz frame rate and down to 0.65 ms shutter time. The camera has  $1280 \times 1024$  pixels with a size of  $\mu\text{m} \times \mu\text{m}$ , and we use a  $10\times$  microscope objective with 4 mm working distance (Plan Apo, Nikon, Minato, Japan) attached to the camera *via* a tubus lens (InfiniTube, Edmund Optics, Barrington, USA). The minimum radius of the capillary bridge is detected using self-written image analysis software,<sup>31</sup> and once the parallel filament is formed, we use the following equation to fit the temporal evolution of the radius  $h(t)$ :

$$h(t) = A \exp\left(-\frac{t-B}{\lambda_C}\right) - D \quad (1)$$

Here,  $\lambda_C$  is the characteristic time scale of the thinning process,  $A + D$  is the radius of the filament at the beginning of the exponential regime,  $B$  defines the corresponding moment in time, and  $D$  is a heuristic offset parameter that can be related to the pre-stretch of the polymers before the parallel filament is formed.<sup>42</sup> For each set of parameters (type of anticoagulant and human or pig blood) at least 20 different CaBER-runs with newly placed droplets are evaluated.


### 2.2 Materials

Human blood is collected from four healthy donors by venipuncture in EDTA-, heparin- or citrate-containing tubes (S-Monovette, Sarstedt, Nümbrecht, Germany). Only for the blood dripping experiment without any anticoagulant, the venipuncture needle is directly connected *via* a Teflon tube to the nozzle of one single donor. The human blood collection is performed following the declaration of Helsinki and is approved by the ethics committee of Ärztekammer des Saarlandes, permit number 51/18. Blood from pig is collected in a similar manner from two different animals as waste material during surgery interventions and used for our experimental investigations within 8 hours.

## 3 Results

Fig. 1(a) illustrates the dynamic evolution of a capillary bridge formed by blood treated with citrate in the context of a capillary






**Fig. 1** Evolution of a capillary bridge of (a) swine and (b) human blood, both anti-coagulated with citrate. Frame rates are 723 and 520 fps, respectively. (c) The minimal filament diameter extracted from the image sequences; closed circles: human blood, open squares: swine blood; numbers in the graph indicate the frame numbers as referenced in (a) and (b). Lines are fits according to eqn (1) for two consecutive elasto-capillary regimes yielding the relaxation times (a) with on-set at frame 13:  $\lambda_C = 5$  ms, and with on-set at frame 21:  $\lambda_C = 13$  ms and (b) with on-set at frame 37:  $\lambda_C = 2$  ms, and with on-set at frame 41:  $\lambda_C = 11.2$  ms.

break-up extensile rheometry (CaBER) experiment. After the initial thinning phase that is primarily governed by the Rayleigh–Plateau instability,<sup>43</sup> the bridge's radius progressively transitions into a self-similar finite-time singularity reminiscent of behavior exhibited by Newtonian fluids.<sup>28</sup> However, a notable departure from this behavior occurs as the flow rate surpasses the characteristic time scale associated with polymer dynamics. At this juncture, the rapid dynamics undergo an abrupt deceleration, leading to the formation of a parallel filament that undergoes exponential thinning over time (Fig. 1(c)). This distinctive phase commences when the filament reaches a thickness on the order of 100  $\mu\text{m}$ . Intriguingly, an additional unexpected shift in behavior manifests as the filament's thickness approaches approximately 10  $\mu\text{m}$ . At this critical point, a secondary exponential thinning regime emerges, characterized by a notably extended characteristic relaxation time (as detailed in the caption of Fig. 1). Remarkably, the behavior exhibited by swine blood (Fig. 1(a)) closely mirrors that of human blood, with both exhibiting characteristic time scales  $\lambda_C$  on the order of several milliseconds. However, it is crucial to note the substantial variability observed across different experimental runs, a topic that will be elaborated upon in subsequent discussions.


For both human and swine blood samples, the behavior observed with citrate is remarkably consistent with that observed with heparin as the anticoagulant (Fig. 2). In both cases, a two-stage exponential thinning process unfolds, accompanied by a notable degree of variability among different experimental runs. The resemblance in behavior between the two blood types is striking, with quite comparable elongational properties. However, it is noteworthy that the characteristic



**Fig. 2** Evolution of a capillary bridge of (a) swine and (b) human blood, both anti-coagulated with heparine. Frame rate is 1540 fps. (c) The minimal filament diameter extracted from the image sequences; closed circles: human blood, open squares: swine blood; numbers in the graph indicate the frame numbers as referenced in (a) and (b). Lines are fits according to eqn (1) for two consecutive elasto-capillary regimes yielding the relaxation times (a) with on-set at frame 5:  $\lambda_C = 0.9$  ms, and with on-set at frame 9:  $\lambda_C = 4.7$  ms and (b) with on-set at frame 6:  $\lambda_C = 2.2$  ms, and with on-set at frame 12:  $\lambda_C = 5.4$  ms.

time scales  $\lambda_C$  tend to be shorter when heparin replaces citrate as the anticoagulant.

A stark departure from this behavior is observed when EDTA is employed as the anticoagulant (Fig. 3). Under these conditions, the emergence of the two-stage exponential thinning process is conspicuously absent. Instead, the initial exponential thinning regime dominates, characterized by significantly



**Fig. 3** Evolution of a capillary bridge of (a) swine and (b) human blood, both anti-coagulated with EDTA. Frame rate is 1540 fps. (c) The minimal filament diameter extracted from the image sequences; closed circles: human blood, open squares: swine blood; numbers in the graph indicate the frame numbers as referenced in (a) and (b). Lines are fits according to eqn (1) yielding the relaxation times (a) with on-set at frame 7:  $\lambda_C = 0.3$  ms and (b) with on-set at frame 13:  $\lambda_C = 0.3$  ms.



smaller values of the characteristic relaxation time  $\lambda_C$ . Nevertheless, it is noteworthy that both human and swine blood continue to exhibit remarkably similar behavior in the presence of EDTA.

The pronounced variability inherent in our measurements becomes evident upon closer examination of the histogram in Fig. 4. The black bars indicate the characteristic time  $\lambda_C$  from the first thinning regime and the red bars from the second one. Both for the case of citrate and heparine, the onset of the second thinning is detectable in several cases. While the use of citrate as the anticoagulant yields time scales extending beyond 10 ms, there are instances where measurements hover around the 1 ms mark or even less. A similar trend is observed when heparin is employed, albeit the longest characteristic time scales remain below 10 ms here. In contrast, the use of EDTA results in a consistent observation of  $\lambda_C$  values below the 1 ms threshold.

To investigate whether the various anticoagulants either delay or expedite the thinning process relative to untreated blood, we conduct a series of exploratory runs using a pending droplet setup. This arrangement enables us to directly connect a Teflon tube from a venous puncture to the nozzle, facilitating the observation of capillary thinning in untreated blood within a matter of seconds after donation. In cases where blood is treated with anticoagulants, a reservoir is attached to the nozzle. Compared to the CaBER, it is much more difficult to obtain data that could be evaluated, because the detachment process induces always strong oscillations and in many cases the droplet drips asymmetrically from the faucet. We therefore present only exemplary runs in Fig. 5. Notably, the relaxation times associated with full blood samples treated with citrate align closely with the relaxation times determined from samples lacking anticoagulants. A comparison of the time scales  $\lambda_C$  with those obtained from CaBER experiments reveals certain




Fig. 5 Sequences of images of a falling drop through a nozzle at 1540 fps (a) blood without any anticoagulant directly drawn from a donor, full squares in (e)  $\lambda_C = 3.8$  ms; (b) full blood with citrate, open squares,  $\lambda_C = 3.1$  ms; (c) full blood with heparine, open circles,  $\lambda_C = 2$  ms; (d) full blood with EDTA, full circles,  $\lambda_C = 1.5$  ms. (e) Filament thinning and the corresponding fits with eqn (1) (see text). The inset shows a photograph of the pending droplet in front of the microscope lens.

differences, which are typical when comparing CaBER with pending droplet or jet break-up experiments.<sup>44</sup> However, both experimental setups consistently reflect qualitatively the trends induced by the chosen anticoagulant.

## 4 Discussion & conclusion

Our findings unequivocally demonstrate that the choice of anticoagulant exerts a profound influence on the elongational properties of blood. In the case of heparin and citrate, we observe a distinctive two-stage exponential thinning behavior, a phenomenon that raises intriguing questions about the underlying mechanisms. Two plausible explanations emerge from our observations: firstly, it might be a consequence of the presence of different relaxation modes in the plasma polymers (proteins), and this phenomena was already observed in numerical simulations of the multi mode Giesekus model (cp. Fig. 2b in ref. 8) Secondly, it is worth noting that when the second thinning regime commences, the filament thickness is on the order of 10  $\mu\text{m}$ , roughly equivalent to the size of red blood cells. It is a well-established fact that the presence of particles can expedite the pinching process.<sup>35,45</sup> Consequently, it is conceivable that a filament with a thickness below 10  $\mu\text{m}$  might be entirely devoid of blood cells, potentially contributing to the observed behavior. The strong elongational rates in this regime together with the small dimensions suggests that changes in the aggregability of the red blood cells due to the different anticoagulants does not play a significant role here, a hypothesis that dedicated experiments could investigate.

One noteworthy aspect of our results is the significant dispersion in the measured relaxation times for a given set of parameters. This variability presents a less straightforward




Fig. 4 Histograms of relaxation times for the swine (a)–(c) and human (d)–(f) full blood samples treated with anticoagulants: (a) and (d) citrate, (b) and (e) heparine, (c) and (f) EDTA. Black bars indicate the characteristic time scale taken from the first exponential thinning regime and red bars from the second one.



challenge to interpret. While we can only speculate at this juncture, one plausible explanation could be a substantial heterogeneity in the concentrations of plasma proteins within the blood samples, thereby contributing to the observed dispersion.

To further elucidate the impact of different anticoagulants on the thinning process compared to untreated, non-coagulated blood, we conducted dripping droplet experiments. This approach provided a means to directly compare the elongational properties of blood samples subjected to various anticoagulants with those of untreated blood. Intriguingly, our findings indicate that citrate has a negligible effect on the elongational properties of blood, suggesting that it preserves the intrinsic behavior of blood during the thinning process. In contrast, heparin appears to exert an accelerating effect on the thinning process, leading to shorter characteristic relaxation times  $\lambda_C$ . Perhaps the most striking observation is associated with the use of EDTA as an anticoagulant, which markedly alters the characteristic relaxation time  $\lambda_C$  by an order of magnitude, emphasizing the dramatic impact of anticoagulant choice on blood's elongational behavior.

Our data are in overall agreement with what is reported in the literature,<sup>5–9</sup> if one considers the reported anticoagulants and our study clarifies the apparent discrepancies. There is quite some need for a replacement fluid for human blood for any type of experimental investigation and any blood replacement fluid<sup>46,47</sup> that should reflect the droplet forming or flow properties of blood should also reflect the elongational properties. This may be done, *e.g.*, by adding a tiny amount of long chained polyethylenoxide to the replacement solution.<sup>5</sup> In any case, our study also reveals that swine blood is a very good replacement for human blood with respect to the elongational properties.

## Author contributions

DA and CW designed research. JEF performed experiments and evaluated the data. AD performed experiments. CW, DA, JEF and AD wrote the manuscript.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We are grateful for the opportunity to carry on this research as a part of the DFG project WA1336/12-2. JEF thanks the Alexander von Humboldt Foundation.

## References

- S. Chien, S. Usami, R. J. Dellenback and M. I. Gregersen, *Science*, 1967, **157**, 829.
- E. W. Merrill, C. S. Cheng and G. A. Pelletier, *J. Appl. Physiol.*, 1969, **26**, 1–3.
- A. N. Beris, J. S. Horner, S. Jariwala, M. J. Armstrong and N. J. Wagner, *Soft Matter*, 2021, **17**, 10591–10613.
- A. Darras, A. K. Dasanna, T. John, G. Gompper, L. Kaestner, D. A. Fedosov and C. Wagner, *Phys. Rev. Lett.*, 2022, **128**, 088101.
- M. Brust, C. Schaefer, R. Doerr, L. Pan, M. Garcia, P. E. Arratia and C. Wagner, *Phys. Rev. Lett.*, 2013, **110**, 078305.
- A. Kolbasov, P. M. Comiskey, R. P. Sahu, S. Sinha-Ray, A. L. Yarin, B. S. Sikarwar, S. Kim, T. Z. Juby and D. Attinger, *Rheol. Acta*, 2016, **55**, 901–908.
- P. C. Sousa, R. Vaz, A. Cerejo, M. S. N. Oliveira, M. A. Alves and F. T. Pinho, *J. Rheol.*, 2018, **62**, 447–456.
- S. Varchanis, Y. Dimakopoulos, C. Wagner and J. Tsamopoulos, *Soft Matter*, 2018, **14**, 4238–4251.
- S. Kar, A. Kar, K. Chaudhury, T. K. Maiti and S. Chakraborty, *ACS Omega*, 2018, **3**, 10967–10973.
- M. Goldin, J. Yerushalmi, R. Pfeffer and R. Shinnar, *J. Fluid Mech.*, 1969, **38**, 689–711.
- A. V. Bazilevskii, S. I. Voronkov, V. M. Entov and A. N. Rozhkov, *Sov. Phys. Dokl.*, 1981, **26**, 333.
- Y. Amarouchene, D. Bonn, J. Meunier and H. Kellay, *Phys. Rev. Lett.*, 2001, **86**, 3558–3561.
- S. L. Anna and G. H. McKinley, *J. Rheol.*, 2001, **45**, 115.
- C. Clasen, J. P. Plog, W.-M. Kulicke, M. Owens, C. Macosko, L. E. Scriven, M. Verani and G. H. McKinley, *J. Rheol.*, 2006, **50**, 849.
- J. Eggers, M. A. Herrada and J. H. Snoeijer, *J. Fluid Mech.*, 2020, **887**, A19.
- B. A. Toms, *Proc. Int. Cong. Rheol.*, 1949, 135.
- L. Xi, *Phys. Fluids*, 2019, **31**, 121302.
- D. Samanta, Y. Dubief, M. Holzner, C. Schäfer, A. N. Morozov, C. Wagner and B. Hof, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 10557–10562.
- S. S. Datta, A. M. Ardekani, P. E. Arratia, A. N. Beris, I. Bischofberger, G. H. McKinley, J. G. Eggers, J. E. López-Aguilar, S. M. Fielding, A. Frishman, M. D. Graham, J. S. Guasto, S. J. Haward, A. Q. Shen, S. Hormozi, A. Morozov, R. J. Poole, V. Shankar, E. S. G. Shaqfeh, H. Stark, V. Steinberg, G. Subramanian and H. A. Stone, *Phys. Rev. Fluids*, 2022, **7**, 080701.
- F. Mighri, P. J. Carreau and A. Ajji, *J. Rheol.*, 1998, **42**, 1477–1490.
- V. Bergeron, D. Bonn, J. Y. Martin and L. Vovelle, *Nature*, 2000, **405**, 772–775.
- D. Xu, A. Varshney, X. Ma, B. Song, M. Riedl, M. Avila and B. Hof, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 11233–11239.
- C. W. Shields IV, C. D. Reyes and G. P. López, *Lab Chip*, 2015, **15**, 1230–1249.
- Z. Chen, A. Sun, H. Wang, Y. Fan and X. Deng, *Med. Nov. Technol. Devices*, 2019, **3**, 100024.
- P. M. Comiskey, A. L. Yarin and D. Attinger, *Phys. Rev. Fluids*, 2018, **3**, 063901.
- J. Huh, S. Kim, B.-H. Bang, A. Aldalbahhi, M. Rahaman, A. L. Yarin and S. S. Yoon, *Phys. Fluids*, 2024, **36**, DOI: [10.1063/5.0189094](https://doi.org/10.1063/5.0189094).



- 27 F. D. Giudice, *Micromachines*, 2022, **13**, 167.
- 28 J. Eggers, *Rev. Mod. Phys.*, 1997, **69**, 865.
- 29 S. Gier and C. Wagner, *Phys. Fluids*, 2012, **24**, 053102.
- 30 L. Campo-Deaño and C. Clasen, *J. Non-Newtonian Fluid Mech.*, 2010, **165**, 1688–1699.
- 31 J. E. Fiscina, P. Fromholz, R. Sattler and C. Wagner, *Exp. Fluids*, 2013, **54**, 1611.
- 32 J. Dinic and V. Sharma, *Proc. Natl. Acad. Sci. U. S. A.*, 2019, **116**, 8766–8774.
- 33 A. Zell, S. Gier, S. Rafai and C. Wagner, *J. Non-Newtonian Fluid Mech.*, 2010, **165**, 1265–1274.
- 34 A. Jaishankar, V. Sharma and G. H. McKinley, *Soft Matter*, 2011, **7**, 7623.
- 35 A. Lindner, J. E. Fiscina and C. Wagner, *EPL*, 2015, **110**, 64002.
- 36 V. Thiévenaz and A. Sauret, *Proc. Natl. Acad. Sci. U. S. A.*, 2022, **119**, e2120893119.
- 37 G. Tomaiuolo, M. Barra, V. Preziosi, A. Cassinese, B. Rotoli and S. Guido, *Lab Chip*, 2011, **11**, 449–454.
- 38 J. E. Mancuso and W. D. Ristenpart, *Phys. Rev. Fluids*, 2017, **2**, 101101.
- 39 M. Mohri and H. Rezapoor, *Res. Vet. Sci.*, 2009, **86**, 111–114.
- 40 S. Tassi Yunga, A. J. Gower, A. R. Melrose, M. K. Fitzgerald, A. Rajendran, T. A. Lusardi, R. J. Armstrong, J. Minnier, K. R. Jordan, O. J. T. McCarty, L. L. David, P. A. Wilmarth, A. P. Reddy and J. E. Aslan, *J. Thromb. Haemostasis*, 2022, **20**, 1437–1450.
- 41 A. Merlo, S. Losserand, F. Yaya, P. Connes, M. Faivre, S. Lorthois, C. Minetti, E. Nader, T. Podgorski, C. Renoux, G. Coupier and E. Franceschini, *Biophys. J.*, 2023, **122**, 360–373.
- 42 C. Wagner, L. Bourouiba and G. H. McKinley, *J. Non-Newtonian Fluid Mech.*, 2015, **218**, 53–61.
- 43 C. Wagner, Y. Amarouchene, D. Bonn and J. Eggers, *Phys. Rev. Lett.*, 2005, **95**, 164504.
- 44 W. Mathues, S. Formenti, C. McIlroy, O. G. Harlen and C. Clasen, *J. Rheol.*, 2018, **62**, 1135–1153.
- 45 W. Mathues, C. McIlroy, O. G. Harlen and C. Clasen, *Phys. Fluids*, 2015, **27**, 093301.
- 46 L. Campo-Deaño, R. P. A. Dullens, D. G. A. L. Aarts, F. T. Pinho and M. S. N. Oliveira, *Biomicrofluidics*, 2013, **7**, 034102.
- 47 A. Orr, P. Wilson and T. Stotesbury, *Soft Matter*, 2023, **19**, 3711–3722.

